Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen

Patent metadata

Field	Value
Publication number	US-11110156-B2
Application number	US-201816002695-A
Country	US
Kind code	B2
Filing date	Jun 7, 2018
Priority date	Feb 15, 2012
Publication date	Sep 7, 2021
Grant date	Sep 7, 2021

Abstract

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of cancer or tumour diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.

First claim

The invention claimed is:

1. A nucleic acid molecule comprising:
(I) a DNA molecule coding for, from 5 to 3′:
a) a polypeptide coding region, encoding a tumour antigen or an epitope of a tumour antigen;
b) a poly(A) sequence or a polyadenylation signal, and
c) at least one histone stem-loop that encodes a RNA that specifically binds to stem-loop binding protein (SLBP) without a histone downstream element (HDE); or
(II) a RNA molecule comprising, from 5′ to 3′:
a) a polypeptide coding region, encoding a tumour antigen or an epitope of a tumour antigen;
b) a poly(A) sequence, and
c) at least one histone stem-loop that specifically binds to SLBP without a HDE.

2. The nucleic acid molecule according to claim 1 , wherein the tumour antigen or the epitope of a tumour antigen is selected from 5T4, 707-AP, 9D7, AFP, AlbZIP HPG1, alpha-5-beta-1-integrin, alpha-5-beta-6-integrin, alpha-actinin-4/m, alpha-methylacyl-coenzyme A racemase, ART-4, ARTC1/m, B7H4, B AGE-1, BCL-2, bcr/abl, beta-catenin/m, BING-4, BRCA1/m, BRCA2/m, CA 15-3/CA 27-29, CA 19-9, CA72-4, CA125, calreticulin, CAMEL, CASP-8/m, cathepsin B, cathepsin L, CD19, CD20, CD22, CD25, CDE30, CD33, CD4, CD52, CD55, CD56, CD80, CDCl27/m, CDK4/m, CDKN2A/m, CEA, CLCA2, CML28, CML66, COA-1/m, coactosin-like protein, collage XXIII, COX-2, CT-9/BRD6, Cten, cyclin B1, cyclin D1, cyp-B, CYPB1, DAM-10, DAM-6, DEK-CAN, EFTUD2/m, EGFR, ELF2/m, EMMPRIN, EpCam, EphA2, EphA3, ErbB3, ETV6-AML1, EZH2, FGF-5, FN, Frau-1, G250, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE7b, GAGE-8, GDEP, GnT-V, gp100, GPC3, GPNMB/m, HAGE, HAST-2, hepsin, Her2/neu, HERV-K-MEL, HLA-A*0201-R17I, HLA-A11/m, HLA-A2/m, HNE, homeobox NKX3.1, HOM-TES-14/SCP-1, HOM-TES-85, HPV-E6, HPV-E7, HSP70-2M, HST-2, hTERT, iCE, IGF-1R, IL-13Ra2, IL-2R, IL-5, immature laminin receptor, kallikrein-2, kallikrein-4, Ki67, KIAA0205, KIAA0205/m, KK-LC-1, K-Ras/m, LAGE-A1, LDLR-FUT, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A9, MAGE-A10, MAGE-A12, MAGE-B1, MAGE-B2, MAGE-B3, MAGE-B4, MAGE-B5, MAGE-B6, MAGE-B10, MAGE-B16, MAGE-B17, MAGE-C1, MAGE-C2, MAGE-C3, MAGE-D1, MAGE-D2, MAGE-D4, MAGE-E1, MAGE-E2, MAGE-F1, MAGE-H1, MAGEL2, mammaglobin A, MART-1/melan-A, MART-2, MART-2/m, matrix protein 22, MC1R, M-CSF, ME1/m, mesothelin, MG50/PXDN, MMP11, MN/CA IX-antigen, MRP-3, MUC-1, MUC-2, MUM-1/m, MUM-2/m, MUM-3/m, myosin class I/m, NA88-A, N-acetylglucosaminyltransferase-V, Neo-PAP, Neo-PAP/m, NFYC/m, NGEP, NMP22, NPM/ALK, N-Ras/m, NSE, NY-ESO-1, NY-ESO-B, OA1, OFA-iLRP, OGT, OGT/m, OS-9, OS-9/m, osteocalcin, osteopontin, p15, p190 minor bcr-abl, p53, p53/m, PAGE-4, PAI-1, PAI-2, PAP, PART-1, PATE, PDEF, Pim-1-Kinase, Pin-1, Pml/PARalpha, POTE, PRAME, PRDX5/m, prostein, proteinase-3, PSA, PSCA, PSGR, PSM, PSMA, PTPRK/m, RAGE-1, RBAF600/m, RHAMM/CD168, RU1, RU2, S-100, SAGE, SART-1, SART-2, SART-3, SCC, SIRT2/m, Sp17, SSX-1, SSX-2/HOM-MEL-40, SSX-4, STAMP-1, STEAP-1, survivin, survivin-2B, SYT-SSX-1, SYT-SSX-2, TA-90, TAG-72, TARP, TEL-AML1, TGFbeta, TGFbetaRII, TGM-4, TPI/m, TRAG-3, TRG, TRP-1, TRP-2/6b, TRP/INT2, TRP-p8, tyrosinase, UPA, VEGFR1, VEGFR-2/FLK-1, and or WT1.

3. The nucleic acid molecule of claim 1 , wherein the molecule does not comprise a sequence encoding a reporter protein, a marker, or a selection protein.

4. The nucleic acid molecule of claim 1 , wherein the nucleic acid is an RNA.

5. The nucleic acid molecule of claim 1 , wherein the poly(A) sequence comprises a sequence of about 25 to about 400 adenosine nucleotides.

6. The nucleic acid molecule of claim 1 , wherein the polyadenylation signal comprises the consensus sequence NN(U/T)ANA.

7. The nucleic acid molecule of claim 1 , wherein at least one guanosine, uridine, adenosine, thymidine, or cytidine position of the nucleic acid molecule is substituted with an analogue of these nucleotides selected from 2-amino-6-chloropurineriboside-5′-triphosphate, 2-aminoadenosine-5′-triphosphate, 2-thiocytidine-5′-triphosphate, 2-thiouridine-5′-triphosphate, 4-thiouridine-5′-triphosphate, 5-aminoallylcytidine-5′-triphosphate, 5-aminoallyluridine-5′-triphosphate, 5-bromocytidine-5′-triphosphate, 5-bromouridine-5′-triphosphate, 5-iodocytidine-5′-triphosphate, 5-iodouridine-5′-triphosphate, 5-methylcytidine-5′-triphosphate, 5-methyluridine-5′-triphosphate, 6-azacytidine-5′-triphosphate, 6-azauridine-5′-triphosphate, 6-chloropurineriboside-5′-triphosphate, 7-deazaadenosine-5′-triphosphate, 7-deazaguanosine-5′-triphosphate, 8-azaadenosine-5′-triphosphate, 8-azidoadenosine-5′-triphosphate, benzimidazole-riboside-5′-triphosphate, N1-methyladenosine-5′-triphosphate, N1-methylguanosine-5′-triphosphate, N6-methyladenosine-5′-triphosphate, 06-methylguanosine-5′-triphosphate, pseudouridine-5′-triphosphate, or puromycin-5′-triphosphate, and xanthosine-5′-triphosphate.

8. The nucleic acid sequence molecule of claim 1 , wherein the G/C content of the polypeptide coding region is increased compared with the G/C content of the coding region of a wild-type nucleic acid encoding the tumour antigen.

9. The nucleic acid molecule of claim 4 , wherein the RNA comprises a 5′ cap structure and a poly(A) sequence of about 25 to about 400 adenosine nucleotides.

10. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises a sequence of at least 10 consecutive cytidines.

11. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule further comprises a stabilizing sequence from the alpha globin 3′ UTR, positioned 3′ relative to the polypeptide coding region of the nucleic acid molecule.

12. A pharmaceutical composition comprising a nucleic acid molecule of claim 1 and a pharmaceutically acceptable carrier.

13. The pharmaceutical composition of claim 12 , further comprising an adjuvant.

14. The pharmaceutical composition of claim 12 , wherein the composition further comprises a cationic or polycationic compound in complex with the nucleic acid molecule.

15. The pharmaceutical composition of claim 12 , wherein the composition further comprises a polycationic polypeptide in complex with the nucleic acid molecule.

16. The nucleic acid molecule of claim 4 , wherein RNA comprises a polypeptide coding region, encoding an epitope of a tumour antigen.

17. The nucleic acid molecule of claim 16 , wherein the epitope of a tumour antigen is a T-cell epitope.

18. The nucleic acid molecule of claim 16 , wherein the epitope is at least one epitope from KRAS.

Assignees

• Curevac Ag

Inventors

• Thess Andreas
• Schlake Thomas
• Probst Jochen

Classifications

• A61K39/0011 Primary

  Cancer antigens · CPC title

• A61K39/001151

  p53 · CPC title

• A61K39/001184

  Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE · CPC title

• A61K39/001109

  Vascular endothelial growth factor receptors [VEGFR] · CPC title

• A61K39/001188

  NY-ESO · CPC title